Jiangsu Hengrui Pharmaceuticals Co Ltd

Jiangsu Hengrui Pharmaceuticals Co Ltd maintains a strong liquidity position, with a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company's free cash flow of 5.698 billion CNY supports operational flexibility and potential reinvestment opportunities. The operating cash flow of 11.235 billion CNY further reinforces its ability to fund operations and capital expenditures without external financing. The company's profitability is robust, with a return on equity (ROE) of 12.58% and a return on assets (ROA) of 11.04%. These metrics exceed the typical benchmarks for the pharmaceutical industry, suggesting efficient use of equity and assets to generate returns. The operating income of 8.819 billion CNY and net income of 7.711 billion CNY reflect strong performance in a competitive market. Jiangsu Hengrui Pharmaceuticals Co Ltd operates in both domestic and foreign markets, with a broad portfolio of products across multiple therapeutic areas. The company's revenue is not disclosed by segment or geography, but its diversified product line suggests a balanced exposure to various market conditions. The absence of detailed segment data limits the ability to assess specific revenue concentration risks. The company's growth trajectory is supported by strong revenue of 31.629 billion CNY and a positive outlook for future performance. Analysts have provided a mean price target of 95.92 CNY and a median price target of 93.50 CNY, with a mean recommendation of 2.00 (1=strong buy, 5=strong sell). The company's capital expenditure of -2.962 billion CNY indicates a reduction in investment, which may be a strategic decision to preserve cash or a sign of operational efficiency. The risk assessment for Jiangsu Hengrui Pharmaceuticals Co Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. However, the absence of long-term debt and strong cash flow metrics mitigate this risk. The company has not disclosed any recent events or filings that would significantly impact its operations or financial position. Recent analyst estimates and recommendations suggest a generally positive outlook for the company. The mean recommendation of 2.00 indicates a buy rating, with 2 strong-buy, 6 buy, and 2 hold recommendations. The price targets range from 74.00 CNY to 134.00 CNY, with a mean of 95.92 CNY and a median of 93.50 CNY. These estimates reflect a consensus that the company is undervalued and has potential for growth.